Maintenance chemotherapy for ovarian cancer.

ABSTRACT:

Background

Epithelial ovarian cancer accounts for about 90% of all cases of ovarian cancer. Debulking surgery and six courses of platinum-based chemotherapy results in complete clinical remission (CCR) in up to 75% of cases. However, 75% of the responders will relapse within a median time of 18 to 28 months and only 20% to 40% of women will survive beyond five years. It has been suggested that maintenance chemotherapy could assist in prolonging remission. To date, there has not been a systematic review on the impact of maintenance chemotherapy for epithelial ovarian cancer.

Objectives

To assess the effectiveness and toxicity of maintenance chemotherapy for epithelial ovarian cancer and to evaluate the impact on quality of life (QoL).

Search methods

In the original rev

SUBMITTER: Mei L 

PROVIDER: S-EPMC6457821 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature